Related Experiment Videos
Combining aspirin with angiotensin converting enzyme inhibitors in heart failure: how safe is it?
Insights
Aspirin and ACE inhibitors may interact adversely in heart failure patients. Clinical judgment is advised until trials clarify risks versus benefits, with aspirin potentially discontinued if a choice is necessary.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Aspirin and ACE inhibitors play crucial roles post-myocardial infarction and in heart failure.
- The interaction between aspirin and ACE inhibitors in heart failure patients requires further clarification.
Purpose of the Study:
- To discuss the potential adverse interactions between aspirin and ACE inhibitors in heart failure.
- To guide clinical decision-making regarding the combined use of these medications.
Main Methods:
- Review of existing data on aspirin and ACE inhibitor interactions.
- Discussion of clinical scenarios, including myocardial infarction and heart failure.
- Highlighting the need for randomized controlled trials.
Main Results:
- High-dose aspirin may interact adversely with ACE inhibitors in heart failure.
- Current data is insufficient to conclusively recommend omitting aspirin.
- Warfarin may be an alternative in severe cases, pending trial data.
Conclusions:
- In myocardial infarction with preserved left ventricular function, combined use at lower doses may be acceptable.
- If one drug must be discontinued in heart failure, aspirin is the preferred choice.
- A definitive randomized trial is needed to establish optimal anti-thrombotic strategies in heart failure.
Abstract:
The above discussion on the interaction of aspirin and ACE inhibitors seems to suggest that aspirin in high doses may have adverse interaction with ACE inhibitors in patients with heart failure but the data obtained is not sufficient or conclusive to recommended omission of aspirin in patients with heart failure. This raises a query in the mind of the physician whether to use a combination or not? The role of aspirin in the early period after myocardial infarction is well established so is the role of ACE inhibitors. Hence in patients with myocardial infarction and preserved left ventricular function it would not be wrong to administer combination of ACE inhibitors and aspirin. Albeit at a lower dose. In patients with large myocardial infarction or heart failure, warfarin may be an option but still needs to be documented in large trials. As suggested long term use of aspirin after infarction is still ambiguous and may be harmful in patients with heart failure with its anticedent side effects. But long term benefits of ACE inhibitors in heart failure are well documented. Hence if a choice has to be made whether to discontinue either of the two drugs it would be preferable to stop the aspirin. To answer the issue of use of aspirin in patients with heart failure it would be essential to conduct a double blind randomized trial comparing known anti-thrombotic treatment, aspirin and anti-coagulants on mortality in patients with heart failure, especially caused by coronary artery disease. Such a trial is underway at the present and till the results are available it should be left to clinical judgement of the physician whether to administer aspirin in patients with heart failure after weighing the benefits versus risk.